IPSEN (OTCMKTS:IPSEY - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $32.42 and last traded at $32.42, with a volume of 1582 shares changing hands. The stock had previously closed at $30.79.
Wall Street Analysts Forecast Growth
Separately, Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating on shares of IPSEN in a research report on Wednesday, April 2nd.
Check Out Our Latest Report on IPSEY
IPSEN Price Performance
The firm has a 50-day moving average price of $29.97 and a 200 day moving average price of $29.57.
IPSEN Increases Dividend
The company also recently disclosed a dividend, which was paid on Wednesday, June 25th. Shareholders of record on Tuesday, June 10th were issued a $0.2896 dividend. This represents a yield of 0.97%. This is a positive change from IPSEN's previous dividend of $0.23. The ex-dividend date of this dividend was Monday, June 9th.
About IPSEN
(
Get Free Report)
Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.
See Also
Before you consider IPSEN, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IPSEN wasn't on the list.
While IPSEN currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
